← Back to Search

Unknown

Dose 1 (Part I) for Renal Hypertension (Target-HTN Trial)

Phase 2
Waitlist Available
Research Sponsored by Mineralys Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks

Summary

This trial is testing a new medication called MLS-101 to see if it can help people with high blood pressure that isn't controlled by other treatments. The study will check if MLS-101 is safe and effective at lowering blood pressure. Researchers hope it works by relaxing blood vessels or reducing fluid in the body.

Eligible Conditions
  • Renal Hypertension

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change From Baseline in Office-measured Systolic Blood Pressure (SBP) at Study Week 8 Compared to Placebo
Secondary study objectives
Change in 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean Systolic Blood Pressure (SBP) and Mean Diastolic Blood Pressure (DBP) From Baseline to End of Treatment (EoT)
Number of Participants With Blood Pressure ≤ 130/80 mmHg at Week 8
Week 8 Change From Baseline in Office-measured Diastolic Blood Pressure (DBP)

Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: Dose 3 (Part I)Experimental Treatment1 Intervention
MLS-101 tablet(s) by mouth once or twice daily.
Group II: Dose 2 (Part I)Experimental Treatment1 Intervention
MLS-101 tablet(s) by mouth once or twice daily.
Group III: Dose 1 (Part I)Experimental Treatment1 Intervention
MLS-101 tablet(s) by mouth once or twice daily.
Group IV: Dose (Part II)Experimental Treatment1 Intervention
MLS-101 tablet(s) by mouth once daily.
Group V: Placebo (Part I)Placebo Group1 Intervention
Placebo tablet(s) by mouth once or twice daily.
Group VI: Placebo (Part II)Placebo Group1 Intervention
Placebo tablet(s) by mouth once daily.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MLS-101 (Part I)
2021
Completed Phase 2
~200
MLS-101 (Part II)
2021
Completed Phase 2
~200

Find a Location

Who is running the clinical trial?

Mineralys Therapeutics Inc.Lead Sponsor
4 Previous Clinical Trials
2,260 Total Patients Enrolled
~46 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top